NEW YORK (GenomeWeb) – MolecularMD today announced it has received approval from the New York State Department of Health for its Notch 1 gene mutation test.

The next-generation sequencing-based test is intended to support clinical trial enrollment, the firm said in a statement, and uses FFPE tissue and whole blood samples. The test has a five-day turnaround time.

Notch 1 mutations have been linked to cancers such as chronic lymphocytic leukemia and mantle cell lymphoma and put patients at greater risk for poor outcomes and reduced overall survival.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.